Peptides for Weight Loss: What Actually Works in 2026
Medically reviewed by the Rite Aid Health Team · Last updated June 16, 2026
Most searches for "peptides for weight loss" are really two different questions. One is about peptides that target body composition directly — tesamorelin for visceral fat, MOTS-c for metabolic function. The other is about GLP-1 medications like semaglutide and tirzepatide, which are peptides too, and which drive the large majority of medical weight loss today. Here's how the peptide options compare — and the right next step for your goal. Still comparing goals? Start with our peptide therapy guide.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
Which option fits your weight-loss goal?
| Peptide | What it targets | Evidence | Route |
|---|---|---|---|
| Tesamorelin | Visceral (abdominal) fat | FDA-approved for HIV-associated lipodystrophy; reduces visceral adipose tissue | Prescription |
| MOTS-c | Metabolic regulation, insulin sensitivity | Mitochondrial-derived peptide; mostly preclinical | Compounding pathway under 2026 review |
| GLP-1 medications (semaglutide, tirzepatide) | Appetite, satiety, glucose | FDA-approved, large clinical trial base | Prescription — see the readiness quiz |
Tesamorelin — the FDA-approved option
Tesamorelin is the one peptide on this page with an FDA approval tied to fat. It's a growth-hormone-releasing hormone analog approved to reduce visceral adipose tissue (the deep abdominal fat around the organs) in a specific population. It raises growth hormone and IGF-1, which shifts body composition toward less visceral fat. It is not a general weight-loss drug and does not drive the appetite suppression GLP-1s do, but for visceral fat specifically it has the strongest evidence here.
MOTS-c — the metabolic peptide
MOTS-c is a mitochondrial-derived peptide studied for its effects on insulin sensitivity, glucose handling, and metabolic flexibility. The human evidence is early. It's one of the seven peptides under formal compounding review in 2026, so it belongs in the exploratory category rather than the proven weight-loss category.
Where GLP-1 medications fit
If your goal is appetite-driven weight loss, GLP-1 receptor agonists — semaglutide and tirzepatide — are the established medical path, with the largest clinical trial base of anything on this page. They're peptides, but they work on a different axis: satiety and glucose regulation rather than growth hormone. If you're weighing a GLP-1, take the GLP-1 weight-loss readiness quiz to see where you stand before a consultation.
How they work for weight loss
These peptides don't share one mechanism — which is why "best peptide for weight loss" has no single answer:
- Tesamorelin signals the pituitary to release growth hormone, which raises IGF-1 and preferentially mobilizes visceral fat.
- MOTS-c acts inside the mitochondria to influence how cells use glucose and fat for energy, improving metabolic efficiency in research models.
- GLP-1 medications slow gastric emptying and act on appetite centers in the brain, reducing how much you eat.
Growth-hormone peptides and GLP-1s can complement different goals — body recomposition versus appetite-driven loss — but they should only be combined under a provider's supervision.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
Blood work before a weight-loss cycle
Establish a baseline before starting anything, and re-test during the cycle to see whether it's working:
- Comprehensive Metabolic Profile — glucose, liver enzymes, and kidney function (eGFR); the safety baseline for any cycle and a glucose readout for metabolic peptides.
- Men's Hormone Health Checkup / Women's Hormone Health Checkup — hormones that drive body composition, including the IGF-1 axis tesamorelin moves.
Baseline tests before a peptide cycle
Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.
Early access
Rite Aid is preparing compounded peptide consultations. Join the waitlist to claim 20% off your first order when consultations and ordering open.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
FAQ
There's no single answer. Tesamorelin has the strongest evidence for visceral (abdominal) fat and is FDA-approved for a specific use. MOTS-c targets metabolic function and is still early in human research. For appetite-driven weight loss, GLP-1 medications like semaglutide and tirzepatide have the largest clinical base.
Yes. Semaglutide and tirzepatide are peptide-based GLP-1 receptor agonists. They work on appetite and glucose regulation rather than growth hormone. Take the readiness quiz if you're considering one.
Tesamorelin and GLP-1 medications do. MOTS-c is moving toward compounding-pharmacy access through the 2026 regulatory process. Work with a licensed provider.
A comprehensive metabolic profile for glucose, liver, and kidney function, plus a hormone panel. Test at baseline and again during the cycle.
It varies by peptide and goal. Tesamorelin's effect on visceral fat is typically assessed over months. GLP-1 medications produce appetite changes within weeks.